Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer

Journal of Urology

Volumn 195, Issue 3, 2016, Pages 612-618

  Shore, Neal D ^a   Kella, Naveen ^b   Moran, Brian ^c   Boczko, Judd ^d   Bianco, Fernando J ^e   Crawford, E David ^g   Davis, Thaylon ^h   Roundy, Kirstin M ^h   Rushton, Kristen ^h   Grier, Charles ^h   Kaldate, Rajesh ^h   Brawer, Michael K ^h   Gonzalgo, Mark L ^f  

^a Carolina Urologic Research Center   (United States)

^b Urology and Prostate Institute   (United States)

^c Prostate Cancer Foundation of Chicago   (United States)

^d WestMed Medical Group   (United States)

^e Urological Research Network   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h Utah   (United States)

Author keywords

biological markers; data collection; evaluation studies; prostatic neoplasms

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CELL CYCLE PROGRESSION; CELL CYCLE PROGRESSION TEST; CHARLSON COMORBIDITY INDEX; CRYOSURGERY; FOLLOW UP; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; OPEN STUDY; PATIENT DECISION MAKING; PELVIS LYMPHADENECTOMY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; PROTON THERAPY; CELL CYCLE; CLINICAL PRACTICE; MIDDLE AGED; PATHOLOGY; PATIENT PREFERENCE; PHYSIOLOGY; PROSTATIC NEOPLASMS; REGISTER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PATIENT PREFERENCE; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; REGISTRIES;

EID: 84975896708     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.09.072     Document Type: Article

References (28)

1. 1 Surveillance, Epidemiology, and End Results Program: SEER Stat Fact Sheets: Prostate, 2012, Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, Bethesda: U.S.
2. 2 Holmstrom, B., Johansson, M., Bergh, A., et al. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ, 339, 2009, b3537.
3. 3 Thompson, I.M., Pauler, D.K., Goodman, P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med, 350, 2004, 2239.
4. 4 Carter, H.B., Albertsen, P.C., Barry, M.J., et al. Early detection of prostate cancer: AUA Guideline. J Urol, 190, 2013, 419.
5. 5 Cooperberg, M.R., Freedland, S.J., Pasta, D.J., et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer, 107, 2006, 2384.
6. 6 Welch, H.G., Albertsen, P.C., Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst, 101, 2009, 1325.
7. 7 Albertsen, P.C., Hanley, J.A., Fine, J., 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA, 293, 2005, 2095.
8. 8 Andriole, G.L., Crawford, E.D., Grubb, R.L. 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med, 360, 2009, 1310.
9. 9 Bill-Axelson, A., Holmberg, L., Ruutu, M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med, 352, 2005, 1977.
10. 10 Cooperberg, M.R., Broering, J.M., Carroll, P.R., Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol, 28, 2010, 1117.
11. 11 Eastham, J.A., Kattan, M.W., Fearn, P., et al. Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. Eur Urol, 53, 2008, 347.
12. 12 Draisma, G., Etzioni, R., Tsodikov, A., et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst, 101, 2009, 374.
13. 13 Center for Medical Technology Policy (CMTP): Effectiveness Guidance Document: Evaluation of Clinical Validity and Clinical Utility of Actionable Molecular Diagnostic Tests in Adult Oncology. Baltimore, Maryland: Center for Medical Technology Policy 2013.
14. 14 Boström, P.J., Bjartell, A.S., Catto, J.W., et al. Genomic predictors of outcome in prostate cancer. Eur Urol, 68, 2015, 1033.
15. 15 Myriad Genetic Laboratories: Prolaris® Biopsy Technical Specifications, 2014. Available at https://s3.amazonaws.com/myriad-library/technical-specifications/Prolaris+Tech+Specs+-+Biopsy+.pdf.
16. 16 Cuzick, J., Swanson, G.P., Fisher, G., et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol, 12, 2011, 245.
17. 17 Cuzick, J., Berney, D.M., Fisher, G., et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer, 106, 2012, 1095.
18. 18 Cooperberg, M.R., Simko, J.P., Cowan, J.E., et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol, 31, 2013, 1428.
19. 19 Freedland, S.J., Gerber, L., Reid, J., et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys, 86, 2013, 848.
20. 20 Bishoff, J.T., Freedland, S.J., Gerber, L., et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol, 192, 2014, 409.
21. 21 Cuzick, J., Stone, S., Fisher, G., et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer, 113, 2015, 382.
22. 22 Sommariva, S., Tarricone, R., Lazzeri, M., et al. Prognostic value of the cell cycle progression score in patients with prostate cancer: a systematic review and meta-analysis. Eur Urol, 2014 Epub ahead of print.
23. 23 Thompson, I., Thrasher, J.B., Aus, G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol, 177, 2007, 2106.
24. 24 Penson, D.F., Chan, J.M., Prostate cancer. J Urol, 177, 2007, 2020.
25. 25 Crawford, E.D., Shore, N., Scardino, P.T., et al. Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. J Clin Oncol, 33(suppl.), 2015 abstract 64.
26. 26 Crawford, E.D., Scholz, M.C., Kar, A.J., et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin, 30, 2014, 1025.
27. 27 Chou, R., Croswell, J.M., Dana, T., et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med, 155, 2011, 762.
28. 28 National Comprehensive Cancer Network: Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology 2015.